A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2009
At a glance
- Drugs Sotatercept (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Acceleron Pharma
- 11 Sep 2009 Pharmacodynamic outcomes have been presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research.
- 08 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jul 2008 New trial record.